Mike A Clark

Title: Mike A Clark: Innovator in Cancer Treatment

Introduction

Mike A Clark is a notable inventor based in Lexington, KY (US), recognized for his contributions to cancer treatment through innovative therapies. With a total of 7 patents, he has made significant strides in the field of medical science, particularly in the modification of tumor necrosis factor and arginine deiminase.

Latest Patents

Among his latest patents, one focuses on a modified tumor necrosis factor. This invention involves modifying TNF with polyethylene glycol (PEG) that has an approximate weight average molecular weight ranging from about 10,000 to about 40,000, preferably between 20,000 and 30,000. This modification significantly increases the circulating half-life of TNF while not increasing its toxicity. Consequently, lower doses of TNF can be administered to effectively treat tumors with fewer accompanying adverse side effects for patients. Another significant patent is directed towards a method of treatment with modified arginine deiminase. This invention involves arginine deiminase modified with polyethylene glycol and outlines methods for treating cancer and inhibiting metastasis.

Career Highlights

Throughout his career, Mike A Clark has worked with various companies, including Phoenix Pharmacologics, Inc. and Phoenix Pharmacologies, Inc. His work has been pivotal in advancing therapeutic methods that aim to improve patient outcomes in cancer treatment.

Collaborations

Mike has collaborated with notable individuals in his field, including Charles Mark Ensor and Frederick Wayne Holtsberg. These collaborations have contributed to the development of innovative solutions in cancer therapy.

Conclusion

Mike A Clark's innovative work in modifying tumor necrosis factor and arginine deiminase showcases his commitment to improving cancer treatment. His contributions have the potential to significantly enhance patient care and treatment efficacy.